BR112017002403A2 - formas de cristais de inibidores de glutaminase - Google Patents

formas de cristais de inibidores de glutaminase

Info

Publication number
BR112017002403A2
BR112017002403A2 BR112017002403A BR112017002403A BR112017002403A2 BR 112017002403 A2 BR112017002403 A2 BR 112017002403A2 BR 112017002403 A BR112017002403 A BR 112017002403A BR 112017002403 A BR112017002403 A BR 112017002403A BR 112017002403 A2 BR112017002403 A2 BR 112017002403A2
Authority
BR
Brazil
Prior art keywords
crystal forms
glutaminase inhibitors
methods
crystalline
crystalline salt
Prior art date
Application number
BR112017002403A
Other languages
English (en)
Portuguese (pt)
Inventor
N Williams Jacqueline
J Springer James
F Stanton Timothy
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of BR112017002403A2 publication Critical patent/BR112017002403A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112017002403A 2014-08-07 2015-08-07 formas de cristais de inibidores de glutaminase BR112017002403A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462034547P 2014-08-07 2014-08-07
PCT/US2015/044301 WO2016022969A1 (en) 2014-08-07 2015-08-07 Crystal forms of glutaminase inhibitors

Publications (1)

Publication Number Publication Date
BR112017002403A2 true BR112017002403A2 (pt) 2017-12-05

Family

ID=55264662

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017002403A BR112017002403A2 (pt) 2014-08-07 2015-08-07 formas de cristais de inibidores de glutaminase

Country Status (13)

Country Link
US (2) US10316030B2 (enExample)
EP (1) EP3193876B1 (enExample)
JP (3) JP6889101B2 (enExample)
KR (1) KR20170082494A (enExample)
CN (1) CN106999490A (enExample)
AU (2) AU2015300825B2 (enExample)
BR (1) BR112017002403A2 (enExample)
CA (1) CA2957225A1 (enExample)
EA (1) EA037738B1 (enExample)
IL (1) IL250391B (enExample)
MX (1) MX2017001620A (enExample)
SG (1) SG11201700816YA (enExample)
WO (1) WO2016022969A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2420498T (lt) 2006-09-26 2017-10-25 Celgene Corporation 5-pakeistieji chinazolinono dariniai, kaip priešvėžiniai agentai
EA026100B1 (ru) 2011-03-11 2017-03-31 Селджин Корпорейшн Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2,6-диона и их фармацевтические композиции и применение
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
WO2014039421A1 (en) 2012-09-04 2014-03-13 Celgene Corporation Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof
PT2920168T (pt) 2012-11-16 2021-10-18 Calithera Biosciences Inc Inibidores heterocíclicos de glutaminase
EA036001B1 (ru) 2014-06-13 2020-09-11 Калитера Байосайенсиз, Инк. Комбинация эрлотиниба и ингибитора глутаминазы для лечения рака легких
CA2957225A1 (en) 2014-08-07 2016-02-11 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
EP3277276B1 (en) * 2015-03-30 2020-11-04 Calithera Biosciences, Inc. Methods of administering glutaminase inhibitors
SG11201708153XA (en) 2015-04-06 2017-11-29 Calithera Biosciences Inc Treatment of lung cancer with inhibitors of glutaminase
JP6971239B2 (ja) 2015-10-05 2021-11-24 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤とイムノオンコロジー薬剤との併用療法
US10278968B2 (en) 2016-08-25 2019-05-07 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
CN109982703A (zh) 2016-08-25 2019-07-05 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂的组合疗法
WO2019089854A1 (en) * 2017-10-31 2019-05-09 President And Fellows Of Harvard College Methods and compositions for treating acute myeloid leukemia
JP2022528355A (ja) * 2019-03-26 2022-06-10 トニックス ファーマ ホールディングス リミテッド Ｓ－（ｎ，ｎ－ジエチルカルバモイル）グルタチオンの塩形態
CN114295836B (zh) * 2021-12-22 2024-12-31 融智生物科技（青岛）有限公司 一种计算设备、存储介质和胶质瘤idh分型检测装置及系统

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1019519A (en) 1911-07-11 1912-03-05 Oscar Martin Polin Apparatus for making backing for teeth.
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
ATE391492T1 (de) 1997-07-29 2008-04-15 Alcon Lab Inc Ophthalmische zusammensetzungen enthaltend galaktomannanpolymere und borat
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
EP1051167A1 (en) 1998-01-29 2000-11-15 Sepracor, Inc. Pharmaceutical uses of optically pure (-) -bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6451828B1 (en) 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
AU2002305926A1 (en) 2001-02-05 2002-10-08 Exegenics Inc. Cysteine protease inhibitors
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
ES2593113T3 (es) 2003-08-07 2016-12-05 Allergan, Inc. Composiciones para el suministro de agentes terapéuticos en los ojos y métodos para obtener y usar los mismos
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
JP4885122B2 (ja) 2004-04-15 2012-02-29 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 癌、器官傷害、および筋肉リハビリテーション／運動過剰訓練についての診断の生物マーカーとしてのタンパク質分解マーカー
RU2009114159A (ru) 2006-09-15 2010-10-20 Селджин Корпорейшн (Us) N-метиламинометилизоидольные соединения, композиции, включающие их, и способы их применения
ES2401557T3 (es) 2007-08-02 2013-04-22 Amgen, Inc Moduladores de Pl3 cinasas y métodos de uso
CN101951930A (zh) 2008-02-19 2011-01-19 阿奈斯特药品株式会社 对身体功能的恢复有用的口服或经肠组合物
WO2010093434A1 (en) 2009-02-11 2010-08-19 Celgene Corporation Isotopologues of lenalidomide
EP2396313A1 (en) 2009-02-11 2011-12-21 Celgene Corporation Isotopologues of thalidomide
PL2536706T3 (pl) 2010-02-11 2017-10-31 Celgene Corp Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
US20130109643A1 (en) 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
US10064885B2 (en) 2010-07-09 2018-09-04 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
US20120302605A1 (en) 2010-11-18 2012-11-29 Deuteria Pharmaceuticals, Llc 3-deutero-pomalidomide
WO2012097116A2 (en) 2011-01-14 2012-07-19 Celgene Corporation Isotopologues of isoindole derivatives
CA2742342A1 (en) 2011-02-12 2012-08-12 Baylor Research Institute Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
FI20115876A0 (fi) 2011-09-06 2011-09-06 Turun Yliopisto Yhdistelmähoito
JP5712882B2 (ja) * 2011-09-28 2015-05-07 株式会社豊田自動織機 電動圧縮機用の電動モータ
CN103030597B (zh) 2011-09-30 2014-10-01 南昌滨西科技有限公司 肾脏型谷氨酰胺酶抑制剂及其制备方法和用途
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
HUE047642T2 (hu) 2011-11-21 2020-05-28 Calithera Biosciences Inc A glutamináz heterociklusos gátlói
WO2013177426A2 (en) 2012-05-24 2013-11-28 Dana-Farber Cancer Institute, Inc. Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer
CA2884103A1 (en) 2012-09-10 2014-03-13 Celgene Corporation Methods for the treatment of locally advanced breast cancer
ES2690829T3 (es) 2012-09-17 2018-11-22 Agios Pharmaceuticals, Inc. Uso de e-cadherina y vimentina para la selección de pacientes que responden al tratamiento
PT2920168T (pt) 2012-11-16 2021-10-18 Calithera Biosciences Inc Inibidores heterocíclicos de glutaminase
CA2892089A1 (en) 2012-11-21 2014-05-30 Rene M. Lemieux Glutaminase inhibitors and methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
SG11201504184PA (en) * 2012-12-03 2015-06-29 Calithera Biosciences Inc Treatment of cancer with heterocyclic inhibitors of glutaminase
WO2015061432A1 (en) 2013-10-25 2015-04-30 Calithera Biosciences, Inc. Treatment of viral infections with inhibitors of glutaminase
WO2015138902A1 (en) 2014-03-14 2015-09-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
US10221459B2 (en) 2014-05-13 2019-03-05 Case Western Reserve University Compositions and methods of treating cancer harboring PIKC3A mutations
EA036001B1 (ru) 2014-06-13 2020-09-11 Калитера Байосайенсиз, Инк. Комбинация эрлотиниба и ингибитора глутаминазы для лечения рака легких
WO2016004418A1 (en) 2014-07-03 2016-01-07 Board Of Regents, University Of Texas System Glutaminase inhibitor therapy
WO2016014890A1 (en) 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
CA2957225A1 (en) 2014-08-07 2016-02-11 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
WO2016054388A1 (en) 2014-10-03 2016-04-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Glutaminase inhibitors
US10517844B2 (en) 2014-11-13 2019-12-31 Buck Institute For Research On Aging Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications
EP3277276B1 (en) 2015-03-30 2020-11-04 Calithera Biosciences, Inc. Methods of administering glutaminase inhibitors
SG11201708153XA (en) 2015-04-06 2017-11-29 Calithera Biosciences Inc Treatment of lung cancer with inhibitors of glutaminase
JP6971239B2 (ja) 2015-10-05 2021-11-24 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤とイムノオンコロジー薬剤との併用療法
US10278968B2 (en) 2016-08-25 2019-05-07 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
CN109982703A (zh) 2016-08-25 2019-07-05 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂的组合疗法
WO2018039442A1 (en) 2016-08-25 2018-03-01 Calithera Biosciences, Inc. Treatment of cancer with inhibitors of glutaminase
KR20190125432A (ko) 2017-03-10 2019-11-06 칼리테라 바이오사이언시즈, 인코포레이티드 글루타미나제 억제제를 사용하는 병용 요법

Also Published As

Publication number Publication date
EA201790337A1 (ru) 2017-09-29
MX2017001620A (es) 2017-05-10
JP2017523991A (ja) 2017-08-24
EP3193876A4 (en) 2017-12-27
CN106999490A (zh) 2017-08-01
AU2015300825A1 (en) 2017-03-09
IL250391A0 (en) 2017-03-30
EP3193876A1 (en) 2017-07-26
EP3193876B1 (en) 2022-01-12
SG11201700816YA (en) 2017-02-27
IL250391B (en) 2021-10-31
AU2015300825B2 (en) 2019-10-10
KR20170082494A (ko) 2017-07-14
US20190359607A1 (en) 2019-11-28
AU2019284149A1 (en) 2020-01-30
US10676472B2 (en) 2020-06-09
WO2016022969A1 (en) 2016-02-11
EA037738B1 (ru) 2021-05-17
JP6889101B2 (ja) 2021-06-18
JP2021165286A (ja) 2021-10-14
US20170226101A1 (en) 2017-08-10
US10316030B2 (en) 2019-06-11
CA2957225A1 (en) 2016-02-11
JP2020037588A (ja) 2020-03-12

Similar Documents

Publication Publication Date Title
BR112017002403A2 (pt) formas de cristais de inibidores de glutaminase
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
MX391812B (es) Agonista fxr derivado de esteroides.
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
BR112018008918A8 (pt) compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
BR112018002499A2 (pt) método de preparação de um composto da fórmula (a) ou um seu sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável, composto produzido pelo método e composição farmacêutica
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
BR112017011972A2 (pt) derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais
BR112017013440A2 (pt) compostos de isoquinolina para o tratamento de hiv
DOP2017000178A (es) Inhibidores selectivos de bace1
EA201890767A1 (ru) C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
BR112017015852A2 (pt) forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1
BR112016024473A2 (pt) composto, composição farmacêutica, e, método para tratamento de uma doença e/ou condição
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
EA201692470A1 (ru) Фармацевтические комбинации
MX384798B (es) Piridinona dicarboxamida para uso como inhibidores de bromodominio.
BR112017006002A2 (pt) compostos de imidazopiridazina e seu uso
BR112018003331A2 (pt) sondas para imagear proteína huntingtina
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements